Comparative Pharmacology
Head-to-head clinical analysis: DILANTIN 125 versus TRIDIONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILANTIN 125 versus TRIDIONE.
DILANTIN-125 vs TRIDIONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenytoin stabilizes neuronal membranes by promoting voltage-gated sodium channel inactivation, reducing high-frequency neuronal firing and seizure propagation.
Increases seizure threshold by modulating voltage-gated sodium channels and enhancing GABA-ergic inhibition.
300-400 mg per day orally in divided doses (e.g., 100 mg three times daily); loading dose 1 g orally divided into three doses given at 2-hour intervals, then 100 mg every 6-8 hours for first 24 hours.
300-600 mg orally three times daily; titrate to seizure control.
None Documented
None Documented
Terminal half-life: 7-42 hours (mean 22 hours) in adults; dose-dependent due to saturable metabolism. Steady-state reached in 7-10 days.
16-24 hours (trimethadione); dimethadione (active metabolite) has a half-life of ~6-12 days, leading to drug accumulation.
Renal: 70% as metabolites (mainly HPPA glucuronide and sulfate), 5-10% as unchanged drug. Fecal: 30% (minor).
Renal: ~70% as unchanged drug and metabolites (including dimethadione); biliary/fecal: minimal (<10%).
Category C
Category C
Anticonvulsant
Anticonvulsant